Taxorest®
Biologically active food supplement TAXOREST® contains a complex of low molecular weight pep-
tides with a molecular weight of up to 5000 Da, isolated from the tissues of the bronchial mucosa of
young animals - calves not older than 12 months of age or pigs.
TAXOREST® is available in capsules with an active substance content of 10 mg.
TAXOREST®’s peptides regulate metabolic processes in the bronchial mucosa cells, increase their re-
serve capacity, have a beneficial effect on the adaptation processes of the body in extreme conditions,
have antioxidant properties, and regulate the processes of peroxidation in the tissues of the bronchial
mucosa. Experimental studies have shown that peptides have a tissue-specific effect on the cells of
those tissues from which they are isolated. This allows us to assume the effectiveness of the use of
TAXOREST® to restore the functions of the respiratory system in case of disorders of various origins,
including a decrease in the reserve capacity of the bronchi when aging.
Chronic bronchitis is a severe medical and social problem due to the high prevalence, growing inci-
dence, and substantial economic damage to society. Chronic bronchitis is the main form in the struc-
ture of chronic nonspecific lung diseases (3, 4).
Medical treatment of chronic bronchitis includes the use of the following drugs (1, 2):
- Antibiotics (penicillin, kanamycin, oleandomycin);
- Sulfa drugs (biseptol, madribone);
- Bronchodilators (aminophylline, ephedrine, salbutamol, phentolamine);
- Expectorants (bromhexine, thermopsis);
- Immunomodulators (thymalin, taktivin);
- Glucocorticoids (hydrocortisone, prednisolone, dexamethasone), etc.
CLINICAL CHARACTERISTICS OF PATIENTS
A clinical study of the effectiveness of TAXOREST® was carried out at the Medical Center of the St.
Petersburg Institute of Bioregulation and Gerontology in the period from April to November 2011.
The study involved 52 patients aged 35 to 73 years, including 35 men and 17 women, with a diagno-
sis of chronic bronchitis and remission phase, divided into 2 groups. In addition to the conventional
treatment, patients of the primary group received TAXOREST® 1 capsule 2 times a day with meals
for 30 days.
The control group included 21 people comparable in diagnosis, sex, and age with the patients of the
primary group. Patients in the control group received only conventional therapy.
Patients in both groups complained of coughing up phlegm, mainly in the morning, general weakness,
sweating, shortness of breath during physical exercises, recurrent attacks of suffocation, sleep distur-
bances, and headaches. All examined patients had severe smoking habits.
RESEARCH METHODS
General clinical examination of blood and urine, biochemical blood study using the REFLOTRON appa-
ratus (Boehringer Mannheim, Germany) were carried out. Also, radiography of the lungs, microscopic
examination of sputum, and analysis of the function of external respiration were performed. Patients’
complaints were assessed in dynamics.
RESEARCH RESULTS
It was found that the use of TAXOREST® in addition to conventional therapy in patients with chronic
bronchitis in 82% of cases contributed to an improvement in well-being, a decrease in the frequency
of coughing attacks, asthma attacks, and a decrease in the amount of sputum secreted. Positive dy-
namics of subjective indicators in the control group were observed in 57% of patients.
Auscultation of the lungs in dynamics showed a decrease in dry and buzzing wheezing.
During the use of TAXOREST®, a decrease in the microscopic structures of sputum was observed:
leukocytes, epithelial cells, Kurshman’s coils, which indicates a decrease in the inflammatory and bron-
chospastic manifestations of the disease.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.